Edition:
United Kingdom

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

3.58USD
5:04pm BST
Change (% chg)

$0.07 (+1.99%)
Prev Close
$3.51
Open
$3.52
Day's High
$3.67
Day's Low
$3.52
Volume
50,385
Avg. Vol
248,905
52-wk High
$4.81
52-wk Low
$2.35

Latest Key Developments (Source: Significant Developments)

Achillion Pharmaceuticals Inc QTRLY Loss Per Share $0.12
Wednesday, 8 Aug 2018 

Achillion Pharmaceuticals Inc ::ACHILLION REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.ACHILLION PHARMACEUTICALS INC - JUNE 30, 2018 CASH POSITION $295.8 MILLION.ACHILLION PHARMACEUTICALS INC - COMPLETED DOSING PHASE 1 CLINICAL STUDY OF ACH-5228 AND INITIATED PHASE 1 STUDY OF ACH-5548.ACHILLION PHARMACEUTICALS INC - GLOBAL PHASE 2 CLINICAL PROGRAMS FOR ACH-4471 CONTINUE TO EXPAND IN PNH AND C3G.ACHILLION PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.12.  Full Article

Achillion Initiates Phase I First-In-Human Study Of ACH-5548
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION INITIATES PHASE I FIRST-IN-HUMAN STUDY OF ACH-5548, A THIRD ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D.ACHILLION PHARMACEUTICALS INC - CONTINUES TO ANTICIPATE PRESENTING RESULTS FROM A 14-DAY PHASE 2 CLINICAL TRIAL OF ACH-4471 IN C3G IN Q3 OF 2018.  Full Article

Achillion Initiates Phase I First-In Study Of ACH-5228
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D.ACHILLION PHARMACEUTICALS INC - COMPANY EXPECTS TO REPORT INTERIM CLINICAL DATA FROM STUDY DURING SECOND HALF OF 2018.  Full Article

Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY.ACHILLION PHARMACEUTICALS INC - INITIATED BIOAVAILABILITY STUDY EVALUATING EXTENDED-RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS.ACHILLION PHARMACEUTICALS INC - INITIATION OF BIOAVAILABILITY STUDY OF EXTENDED RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS.  Full Article

Achillion announces pricing of secondary offering of common stock
Thursday, 16 Nov 2017 

Nov 15 (Reuters) - Achillion Pharmaceuticals Inc :Achillion announces pricing of secondary offering of common stock.Says secondary public offering of 18.4 million common shares priced at $2.75per share.  Full Article

Achillion announces proposed secondary offering of common stock
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion announces proposed secondary offering of common stock.Achillion Pharmaceuticals Inc says ‍intends to offer for sale in an underwritten public offering 18.4 million shares of common stock of achillion​.Achillion Pharmaceuticals - existing stockholder of company, Johnson & Johnson Innovation-JJDC Inc will be making the offering of common stock.Achillion Pharmaceuticals Inc - ‍achillion will not sell any shares or receive any proceeds from offering​.  Full Article

Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Achillion Pharmaceuticals Inc :Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g.Achillion Pharmaceuticals Inc - ‍greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ach-4471​.Achillion Pharmaceuticals Inc - ‍improvement in complement alternative pathway biomarkers observed​.Achillion Pharmaceuticals Inc - ‍preliminary data from phase 2 trial suggest that ach-4471 may reverse ap hyperactivity in c3g​.Achillion Pharma- ‍preliminary data from phase 2 trial suggest ach-4471 may have potential to reverse AP hyperactivity resulting in improvement in proteinuria​.  Full Article

Achillion says ACH-4471 granted orphan drug designation by FDA
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Achillion Pharmaceuticals Inc :Achillion announces ACH-4471 granted orphan drug designation by the FDA and positive opinion for orphan drug designation in the european union for the treatment of paroxysmal nocturnal hemoglobinuria.Achillion Pharma - ‍EMA committee for orphan medicinal products issued a positive opinion on ACH-4471 for orphan status in EU for treatment of PNH​.  Full Article

Achillion Q3 loss per share $0.14
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion reports third quarter 2017 financial results and provides update on clinical programs.Q3 loss per share $0.14.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Achillion Pharma Says Truitt Gets Annualized Base Salary Of $560,000

* ACHILLION PHARMACEUTICALS SAYS JOSEPH TRUITT RECEIVES ANNUALIZED BASE SALARY OF $560,000, IN CONNECTION WITH APPOINTMENT AS CEO - SEC FILING